Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial.
Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, Fukuyama T, Doi Y, Mochizuki S, Izumi T, Takekoshi N, Yoshida K, Hiramori K, Origasa H, Uchiyama S, Matsumoto M, Yamaguchi T, Hori M; Japan Atrial Fibrillation Stroke Trial Group. Sato H, et al. Among authors: origasa h. Stroke. 2006 Feb;37(2):447-51. doi: 10.1161/01.STR.0000198839.61112.ee. Epub 2005 Dec 29. Stroke. 2006. PMID: 16385088 Clinical Trial.
Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, Matsuzaki M, Takeshita A, Origasa H, Matsui K, Hosoda S; MUCHA Investigators. Hori M, et al. Among authors: origasa h. Am Heart J. 2004 Feb;147(2):324-30. doi: 10.1016/j.ahj.2003.07.023. Am Heart J. 2004. PMID: 14760332 Clinical Trial.
Risk evaluation of coronary heart disease and cerebrovascular disease by the Japan Atherosclerosis Society Guidelines 2002 using the cohort of the Holicos-PAT study.
Koizumi J, Shimizu M, Miyamoto S, Takeda R, Ohka T, Kanaya H, Uno Y, Ueda K, Takegoshi T, Wakasugi T, Ohta M, Sumitani T, Kametani T, Watanabe A, Fujita H, Hifumi S, Origasa H, Mabuchi H. Koizumi J, et al. Among authors: origasa h. J Atheroscler Thromb. 2005;12(1):48-52. doi: 10.5551/jat.12.48. J Atheroscler Thromb. 2005. PMID: 15725696 Free article.
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Yokoyama M, et al. Among authors: origasa h. Lancet. 2007 Mar 31;369(9567):1090-8. doi: 10.1016/S0140-6736(07)60527-3. Lancet. 2007. PMID: 17398308 Clinical Trial.
Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial.
Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, Matsuzawa Y, Sasaki J, Oikawa S, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; JELIS Investigators, Japan. Tanaka K, et al. Among authors: origasa h. Stroke. 2008 Jul;39(7):2052-8. doi: 10.1161/STROKEAHA.107.509455. Epub 2008 May 1. Stroke. 2008. PMID: 18451347 Clinical Trial.
Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).
Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; JELIS Investigators, Japan. Saito Y, et al. Among authors: origasa h. Atherosclerosis. 2008 Sep;200(1):135-40. doi: 10.1016/j.atherosclerosis.2008.06.003. Epub 2008 Jun 19. Atherosclerosis. 2008. PMID: 18667204 Clinical Trial.
Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination.
Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I, Aizawa Y, Yamashita T, Atarashi H, Horie M, Ohe T, Doi Y, Shimizu A, Chishaki A, Saikawa T, Yano K, Kitabatake A, Mitamura H, Kodama I, Kamakura S. Inoue H, et al. Among authors: origasa h. Int J Cardiol. 2009 Oct 2;137(2):102-7. doi: 10.1016/j.ijcard.2008.06.029. Epub 2008 Aug 8. Int J Cardiol. 2009. PMID: 18691774
Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled,double-blind study (J-BAF Study).
Yamashita T, Ogawa S, Sato T, Aizawa Y, Atarashi H, Fujiki A, Inoue H, Ito M, Katoh T, Kobayashi Y, Koretsune Y, Kumagai K, Niwano S, Okazaki O, Okumura K, Saku K, Tanabe T, Origasa H; J-BAF Investigators. Yamashita T, et al. Among authors: origasa h. Circ J. 2009 Jun;73(6):1020-7. doi: 10.1253/circj.cj-08-1061. Epub 2009 Apr 9. Circ J. 2009. PMID: 19359813 Free article. Clinical Trial.
263 results